Skip to main content

To: Jeremy Hunt

PLEASE re-instate P.R.R.T on the Cancer Drugs Fund in England

PRRT is a proven drug treatment for Neuroendocrine Tumours. It is the standard of care in Europe. It was removed from the Cancer Drugs Fund in September 2015, ostensibly because there was no formal clinical trial proving its efficacy. ONE WEEK later, the medical evidence from the Netter 1 Study was published showing that this treatment had a tremendous positive effect on progression free survival.

Why is this important?

In 2014 my husband Joe Bohen was diagnosed with a rare form of cancer: Neuroendocrine Tumours (NET.) It had already spread from his lungs to his liver, lymph nodes and spine when discovered and is inoperable, BUT the disease has been controlled by Lanreotide and he has since enjoyed a good quality of life. However, in March we were told that the tumours were growing again. As if that news wasn't bad enough, we were told that PRRT which could very likely stop further growth, was removed from the Cancer Drugs Fund last September and he can't have the drug.

PRRT is available throughout Europe and in other parts of the UK - this decision only affects people living in England. How fair is that? Would Bruce Keogh (Chief Executive of NHS England) or Jeremy Hunt (Health Secretary) be happy if a member of their family needed this drug but was denied it because of their post code?
Apparently, NICE are considering PRRT. Their deliberations will take until Autumn of 2017. That will simply be too late for Joe and hundreds of others living with this rare form of cancer. Please sign the petition to reverse this outrageous health inequality.

Category

Updates

2016-04-15 16:26:34 +0100

1,000 signatures reached

2016-04-14 22:43:03 +0100

500 signatures reached

2016-04-14 16:38:12 +0100

100 signatures reached

2016-04-14 15:47:04 +0100

50 signatures reached

2016-04-14 14:46:32 +0100

25 signatures reached

2016-04-14 14:28:31 +0100

10 signatures reached